May 20 (Reuters) - Marker Therapeutics Inc MRKR.O:
MARKER THERAPEUTICS REPORTS THAT LYMPHODEPLETION IMPROVES THE EXPANSION AND PERSISTENCE OF MULTI-ANTIGEN RECOGNIZING T CELLS IN PATIENTS WITH LYMPHOMA
Source text: ID:nGNX5q2KmX
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))